The U.S. Food and Drug Administration (FDA) has cleared Cepheid’s Xpert Respiratory Panel, a multiplex PCR test that detects 13 common viral and bacterial respiratory pathogens from a single nasopharyngeal swab. Cepheid announced the clearance on September 29, 2026, and said the test will start shipping to U.S. customers in the coming weeks.
Intended use
The panel is cleared to aid in the diagnosis of respiratory tract infection in people with clinical signs and symptoms. As with other syndromic panels, results are meant to be interpreted together with clinical, epidemiological, and other laboratory findings.
Respiratory infections caused by different organisms often look alike at the bedside. Fever, cough, and shortness of breath do not tell a clinician whether the cause is a virus or a bacterium, let alone which one. A multiplex panel tests one sample for many targets at once, instead of running single-target tests one after another.
Runs on existing GeneXpert systems
The test runs on Cepheid’s GeneXpert systems, the company’s cartridge-based molecular platform. Cepheid says hands-on time is under one minute. Laboratories that already operate GeneXpert instruments can add the panel without new hardware.
Focus on high-acuity patients
Cepheid positions the panel for patients where a precise result matters most. “The Xpert Respiratory Panel is designed to support high-acuity respiratory testing. It helps clinicians make informed decisions by focusing on specific pathogen targets,” said Dr. Connie Savor, Chief Medical Officer at Cepheid.
The company links the panel to diagnostic stewardship and to more responsible antibiotic use. Most respiratory infections are viral, and a confirmed viral result can help avoid unnecessary antibiotics; a bacterial result can speed up targeted treatment. Cepheid did not release new clinical study data with the announcement. It cited published studies showing that rapid multiplex PCR can shorten time to results and may support clinical management in hospitals.
Context
The clearance adds to a growing number of multiplex respiratory PCR assays available to U.S. laboratories. When comparing them, labs typically look at the target menu, hands-on time, turnaround time, and whether the assay runs on instruments they already have.
Photo: Coolcaesar, CC BY-SA 4.0, via Wikimedia Commons